A carregar...
Reasons Why Post-Trial Access to Trial Drugs Should, or Need not be Ensured to Research Participants: A Systematic Review
Background: researchers and sponsors increasingly confront the issue of whether participants in a clinical trial should have post-trial access (PTA) to the trial drug. Legislation and guidelines are inconsistent, ambiguous or silent about many aspects of PTA. Recent research highlights the potential...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3133737/ https://ncbi.nlm.nih.gov/pubmed/21754950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/phe/phr013 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|